Back to news

Erasca Reports Broad and Robust Phase 1 Clinical Efficacy and Favorable Safety Data for Pan-RAS Molecular Glue ERAS-0015

Globe Newswire•20/11/2026•07:00 ET
0

Key Highlights

  • ➤ERAS-0015 achieved 44% confirmed ORR in 2L+ KRAS G12X PDAC.
  • ➤ERAS-0015 achieved 69% confirmed ORR in KRAS G12D or G12V PDAC.
  • ➤ERAS-0015 achieved 60% confirmed ORR in post-ICI/platinum KRAS G12X NSCLC.
  • ➤Phase 3 1L PDAC trial accelerated to initiate in first half of 2027.
  • ➤ERAS-4001 showed preliminary antitumor activity supporting planned 2027 combination escalation.

Expert Statements

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“These compelling results highlight the strength and breadth of ERAS-0015’s clinical activity across several tumor types”

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“We are particularly encouraged by confirmed responses in common KRAS mutation subtypes, including G12D and G12V, which together occur in nearly 70% of patients with pancreatic cancer.”

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“Importantly, we believe the robust clinical activity observed in this heavily pretreated population, which included a high proportion of patients whose tumors harbored less sensitive mutations, compares favorably with reported activity for other pan-RAS and mutant-selective inhibitors, subject to the limitations of cross-study comparisons.”

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“Additionally, we believe these efficacy results, coupled with generally well-tolerated safety data and low rates of dose interruptions, reductions, and discontinuations at 32 mg once daily, support advancing ERAS-0015 toward multiple potentially registration-enabling trials.”

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“Early combination data demonstrating favorable tolerability results with chemotherapy, an immune checkpoint inhibitor, and an anti-EGFR antibody, together with preliminary clinical activity for ERAS-4001, strengthen our rationale for expanding ERAS-0015’s combination potential.”

Jonathan E. Lim, M.D., Chairman, CEO, and co-founder of Erasca

“We expect 2027 to be an important year for our RAS-targeting franchise as we plan to initiate potentially registration-enabling clinical trials in pancreatic and lung cancers and advance combination dose-escalation trials, including the planned ERAS-0015 plus ERAS-4001 combination.”

ERAS-0015 at 32 mg QD achieved 44% confirmed ORR in 2L+ KRAS G12X PDAC, despite heavy pretreatment (84% in the 3L+ setting) and a high proportion of G12R mutations (44% of patients)

ERAS-0015 at 32 mg QD achieved 69% confirmed ORR in 2L+ KRAS G12D or G12V PDAC

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in